Laboratorios Rubió, a CataloniaBio & HealthTech member, will market a non-invasive test to detect non-alcoholic fatty liver and related diseases. The new test is called OWLiver® and has been developed by the biotech firm OWL.
OWLiver® is precise, non-invasive and cheaper than other techniques such as ultrasound or magnetic resonance. OWLiver® is based on the lipidomic analysis of the patients’ blood serum.
With this agreement for Spain and Latin America, Laboratorios Rubió has strengthened its position in the field of in vitro diagnostics (IVD) and metabolomics.
Do you want to know more Laboratorios Rubió? We recommend this video of CataloniaBioHT interviewing them:
Comments